Skip to content
Review

Clinical Characteristics and Visual Outcomes of Optic Neuritis in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Aug 2026 · Journal of neuro-ophthalmology · 0 citations · 20 references
Medicine

TL;DR

Children with MOGAD-associated ON often return to normal visual acuity despite significant optic atrophy and a prospective longitudinal study on pediatric MOGAD-ON is warranted to validate these findings and identify biomarkers for visual outcome prediction.

Abstract

Background

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a neuro-immunological disorder that can cause optic neuritis (ON) and significant visual impairment. Our objective was to investigate clinical characteristics and visual outcomes in children with MOGAD-ON.

Methods

Retrospective cohort study of MOG-IgG-positive children (onset age 18 years and younger) meeting 2023 international MOGAD panel criteria who presented with ON and received neuro-ophthalmic care between 2003 and 2023 at 3 academic centers in Northern California was conducted. We captured demographic and clinical characteristics, disease course, and presenting MOG-IgG titers through chart review. Ophthalmic metrics, including logarithmic minimum angle of resolution best-corrected visual acuity (logMAR BCVA), retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer thicknesses, and automated visual field mean deviation (AVF MD) at diagnosis, 1-month, 6-month, 1-year, and final (2+ years) visits, were obtained.

Results

This study included 49 ON-affected eyes of 29 patients (20 with bilateral involvement), with 19 (66%) being female. The median age at first diagnosis was 9 years (range 1-18). The median follow-up was 40 months (0-119). Age younger than 8 years at MOGAD onset was predictive of recurrent ON (β1=-1.61, P = 0.03). LogMAR BCVA improved from 1.4 at diagnosis to 0.2 at 1 month and 0.07 at the final visit (P < 0.0001). In total, 29 eyes (59%) of 22 patients (76%) achieved complete visual recovery (BCVA LogMAR 0). RNFL thickness decreased from mean 130 µm at diagnosis to 6 months (65 µm, P < 0.05). Average AVF MD improved from -12.8 dB at diagnosis to -5.4 dB at the final visit (P = 0.02). Higher presenting MOG-IgG titers were associated with worse presenting visual fields (r = -0.96, P = 0.04).

Conclusions

Children with MOGAD-associated ON often return to normal visual acuity despite significant optic atrophy. Most RNFL thinning occurs in the first 6 months but continues beyond 2 years after MOGAD onset. Younger children were at greater risk of ON relapse. A prospective longitudinal study on pediatric MOGAD-ON is warranted to validate these findings and identify biomarkers for visual outcome prediction.

View source

Similar papers

Review Sep 2026

A Study on the Correlation Between Clinical Features of Chronic Relapsing Inflammatory Optic Neuropathy and Myelin Oligodendrocyte Glycoprotein Antibodies.

BACKGROUND To compare clinical characteristics, cerebrospinal fluid (CSF) findings, relapse patterns, MRI features, visual outcomes, and optical coherence tomography (OCT) structural changes between MOG-IgG-positive and seronegative patients with chronic relapsing inflammatory optic neuritis (CRION). METHODS I retros...

Xin Zhang · 0 citations
Open access Sep 2026

Multimodal Characterization of Optic Neuritis in Demyelinating Disease: Clinical Phenotypes, Neuroimaging, and Visual Biomarkers

The findings support a multimodal diagnostic model in which clinical examination, neuroimaging, retinal structural assessment, functional visual testing, and disease-associated antibodies provide complementary rather than redundant information.

M. García, Frida Desiree Lara Hernández, Jorman Fernando Cazorla Vinueza et al. · 0 citations
Open access Sep 2026

Pediatric myelin oligodendrocyte glycoprotein antibody associated disease following incomplete Kawasaki – a case report with varied association

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as a distinct inflammatory demyelinating disorder of the central nervous system. Although relatively rare, growing recognition of this entity has highlighted important differences from multiple sclerosis and neuromyelitis optica spectru...

Kavya Rajanna, G. Sharma · 0 citations
Sep 2026

Serum NfL predicts visual recovery and neuronal loss after optic neuritis.

Early serum neurofilament light chain may stratify optic neuritis severity and guide neuroprotective trial selection and guide neuroprotective trial selection.

Gloria Dalla Costa, Marco Pisa, R. Furlan et al. · 0 citations
Open access Sep 2026

Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings.

PURPOSE To identify risk factors for relapse in patients with myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON) during the onset event. STUDY DESIGN Retrospective cohort study. METHODS We included 44 eyes of 44 Japanese patients with MOG-ON (median age 40.0 years [interquartile range 2...

Chiaki Yamaguchi, Noriko Himori, Naoki Kiyota et al. · 0 citations
Aug 2026

Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Optic Neuritis With Perineuritis Treated With Immunoadsorption Plasmapheresis in a 91‐Year‐Old Woman: A Case Report

Myelin oligodendrocyte glycoprotein antibody‐associated disease can occur in older adults, but onset in nonagenarians is uncommon. In this age group, acute or subacute visual loss often requires differentiation from ischemic, diabetic retinal, and glaucomatous disorders. A 91‐year‐old woman presented with...

Isamu Takai, Yuji Tomizawa, Y. Hoshino et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.